Galderma’s Nemluvio Brings New Mechanism To Atopic Dermatitis

Nemluvio is the first IL-31 inhibitor approved by the US FDA for atopic dermatitis and will compete with Sanofi/Regeneron’s Dupixent and other, newer IL-13 inhibitors.

(Shutterstock)

Galderma’s Nemluvio (nemolizumab) is the first IL-31 inhibitor approved by the US Food and Drug Administration for the treatment of atopic dermatitis (AD), bringing a new mechanism of action to patients with the condition. Nemluvio – which is Galderma’s first biologic drug – is already available in the US, having been approved by the FDA in August for the treatment of prurigo nodularis (PN).

More from New Products

More from Therapy Areas